Latest Articles

Publication Date
Menopause as a Critical Turning Point in Lipedema: The Estrogen Receptor Imbalance, Intracrine Estrogen, and Adipose Tissue Dysfunction Model.

Lipedema is a chronic, estrogen-sensitive adipose tissue disorder characterized by disproportionate subcutaneous fat accumulation, fibrosis, inflammation, and resistance to fat mobilization. Despite its high prevalence, lipedema remains poorly understood and …

Published: July 23, 2025, midnight
Clinical challenge of benign metastasizing leiomyoma with cardiac and hepatic involvement: A case report.

Benign metastasizing leiomyoma (BML) is a rare disorder occurring in women with a history of uterine leiomyomas and having detection of leiomyomas in extrauterine locations. This case report describes a …

Published: July 7, 2025, midnight
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health

The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health

Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace

Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times

Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire

Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스

Published: May 7, 2025, noon
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial - koreabiomed.com

Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial koreabiomed.com

Published: May 7, 2025, 6:51 a.m.
Uterine fibroids are a common medical condition, and for some women it can be devastating - MSN

Uterine fibroids are a common medical condition, and for some women it can be devastating MSN

Published: April 5, 2025, 7:13 p.m.
'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.

Ovariostasis is a reversible and temporary suspension of the cyclic ovarian activity, characterized by anovulation and hypogonadotropinemia (low serum concentrations of FSH and LH), which can be observed in case …

Published: April 3, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!